You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldt–Jakob disease
  1. Harpreet Hyare1,2,
  2. Anil Ramlackhansingh3,
  3. Giorgio Gelosa3,
  4. Paul Edison3,
  5. Peter Rudge1,2,
  6. Sebastian Brandner4,
  7. David J Brooks3,
  8. John Collinge1,2,
  9. Simon Mead1,2
  1. 1National Prion Clinic, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Trust, London, UK
  2. 2MRC Prion Unit, UCL Institute of Neurology, Queen Square, London, UK
  3. 3MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, London, UK
  4. 4Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Trust, London, UK
  1. Correspondence to Professor David J Brooks, MRC Clinical Sciences Centre, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK; david.brooks{at}csc.mrc.ac.uk

https://doi.org/10.1136/jnnp.2010.233692

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Although PrP-amyloid and amyloid β plaques found in Alzheimer's disease (AD) are composed of different peptides, they share common physicochemical properties,1 including a high β-sheet secondary structure and the binding of agents that label amyloid. As amyloid β load can be measured in patients with AD by use of positron emission tomography (PET) and the radiotracer carbon-11-labelled Pittsburgh compound B (11C-PiB), it is possible that 11C-PiB PET could be an in vivo marker of PrP-amyloid. We evaluated whether 11C-PiB PET can reliably demonstrate the presence of abnormal PrP-amyloid deposition in patients who are affected by, or at risk of, human prion disease. This would be of potential clinical importance in early diagnosis, in identifying asymptomatic patients who might benefit from proposed therapeutic interventions, and in monitoring treatment efficacy.

    Ethical approval for the study was granted by the Research Ethics Committee of the National Hospital for Neurology and Neurosurgery (NHNN) and written informed consent was obtained from subjects. Exclusions included pregnancy, contraindication to MRI, history of cancer in the last 5 years (except skin and prostate) and patients who were unable to give valid informed consent. One patient with variant Creutzfeldt–Jakob disease (vCJD), two symptomatic patients with P102L mutation and two asymptomatic PRNP mutation carriers referred to the National Prion Clinic, NHNN, London, UK, were recruited (four males, age range 25–62 years). Ten control subjects (six males, age range 55–75 years) were also investigated.

    All subjects underwent an MRI examination using a GE Signa LX 1.5T MRI system at NHNN …

    View Full Text

    Footnotes

    • Funding This work was supported by the Department of Health (England) through funding of the National Prion Monitoring Cohort study and by the UK Medical Research Council. Some of this work was undertaken at University College London Hospitals/University College London, which received a proportion of funding from the National Institute for Health Research Comprehensive Biomedical Research Centres funding scheme.

    • Competing interests None.

    • Patient consent Obtained.

    • Ethics approval This study was conducted with the approval of the NHNN and ION Local Research Ethics Committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.